Anthony LaPlaca - Jul 15, 2021 Form 4 Insider Report for INVACARE CORP (IVC)

Role
Sr. VP and General Counsel
Signature
/s/ Anthony C. LaPlaca, by Kristofer K. Spreen, his attorney-in-fact, pursuant to Power of Attorney, dated December 30, 2008, on file with the Commission
Stock symbol
IVC
Transactions as of
Jul 15, 2021
Transactions value $
-$10,878
Form type
4
Date filed
7/16/2021, 04:28 PM
Previous filing
May 18, 2021
Next filing
Mar 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IVC Common Shares Sale -$10.9K -1.4K -1.56% $7.77* 88.4K Jul 15, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IVC Employee Stock Option (Right to Buy) 83.1K Jul 15, 2021 Common Shares 83.1K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.78, inclusive. The reporting person undertakes to provide to Invacare Corporation, any security holder of Invacare Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 No transaction is being reported on this line. Reported on a previously filed Form 3, Form 4, or Form 5.
F4 The reporting person holds previously reported options to buy 83,133 Common Shares (with tandem tax withholding rights) under the Invacare Corporation 2003 Performance Plan and the Invacare Corporation 2013 Equity Compensation Plan, granted in reliance upon the exemption provided by Rule 16b-3. These options were granted between September 2, 2011 and March 16, 2017, at exercise prices between $12.15 to $24.45 per share, will expire between September 2, 2021 and March 16, 2027, and became exercisable between September 30, 2012 and February 19, 2020.